How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

807 results for

Galantamine

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

261. Prescription Patterns of Medications for Alzheimer’s Disease in Japan from 2010 to 2015: A Descriptive Pharmacy Claims Database Study Full Text available with Trip Pro

from community pharmacies across Japan. The study patients were 20 years or older and first administered medications for AD (donepezil, memantine, rivastigmine, or galantamine) between January 2010 and September 2014. They were grouped on the basis of the year of their initial medications for AD administration into the 2010-2011 and 2012-2014 groups (1 and 2, respectively) and their characteristics and AD treatments were summarized by group. The subanalyses used a multivariable logistic regression

2016 Neurology and Therapy

262. Design and synthesis of new piperidone grafted acetylcholinesterase inhibitors Full Text available with Trip Pro

and evaluated in vitro for their acetylcholinesterase (AChE) inhibitory activities. Among the newly synthesized compounds, 5h, 9h, 9j, and 9p displayed higher AChE enzyme inhibitory activities than the standard drug, galantamine, with IC50 values of 0.83, 0.98, and 0.73μM, respectively. Cytotoxicity studies of 5h, 9h, 9j, 9n and 9p on human neuroblastoma cells SH-SY5Y, showed no toxicity up to 40μM concentration. Molecular docking simulations of the active compounds 5h and 9p disclosed the crucial role of π

2016 Bioorganic & medicinal chemistry letters

263. Evaluation of Antioxidant, Anti-cholinesterase, and Anti-inflammatory Effects of Culinary Mushroom Pleurotus pulmonarius Full Text available with Trip Pro

, the standard reference. The ME exhibited significantly higher hydroxyl radical scavenging activity than butylated hydroxytoluene. ME showed slightly lower but moderate inhibitory activity against acetylcholinesterase (AChE) and butyrylcholinesterase than galantamine, a standard AChE inhibitor. It also exhibited protective effect against cytotoxicity to PC-12 cells induced by glutamate (10~100 µg/mL), inhibitory effect on nitric oxide (NO) production and inducible nitric oxide synthase protein expression

2016 Mycobiology

264. Repurposing psychiatric medicines to target activated microglia in anxious mild cognitive impairment and early Parkinson’s disease Full Text available with Trip Pro

enhancers (donepezil, galantamine, memantine); and other drugs (dextromethorphan, quinidine, amantadine). In contrast, pramipexole and methylphenidate might promote microglial activation. The most promising replicated findings of reduced microglial activation are for quetiapine, valproate, lithium, fluoxetine, donepezil, and memantine but further study is needed and translation of their microglial effects to human disease still requires investigation. In AD-relevant models, risperidone, valproate

2016 American journal of neurodegenerative disease

265. Acetylcholinesterase inhibitors (AChEI's) for the treatment of visual hallucinations in schizophrenia: a review of the literature Full Text available with Trip Pro

symptoms. Funding Not stated. Bibliographic details Patel SS, Attard A, Jacobsen P, Shergill S. Acetylcholinesterase inhibitors (AChEI's) for the treatment of visual hallucinations in schizophrenia: a review of the literature. BMC Psychiatry 2010; 10:69 PubMedID DOI Original Paper URL Indexing Status Subject indexing assigned by NLM MeSH Cholinesterase Inhibitors /therapeutic use; Galantamine /therapeutic use; Hallucinations /drug therapy; Humans; Indans /therapeutic use; Phenylcarbamates /therapeutic

2010 DARE.

266. Evolution of the evidence on the effectiveness and cost-effectiveness of acetylcholinesterase inhibitors and memantine for Alzheimer`s disease: systematic review and economic model Full Text available with Trip Pro

Evolution of the evidence on the effectiveness and cost-effectiveness of acetylcholinesterase inhibitors and memantine for Alzheimer`s disease: systematic review and economic model in 2007 the National Institute of Health and Clinical Excellence (NICE) restricted the use of acetylcholinesterase inhibitors and memantine.we conducted a health technology assessment (HTA) of the effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of AD to re (...) and dead. The perspective was NHS and Personal Social Services and the cost year 2009.confidence about the size and statistical significance of the estimates of effect of galantamine, rivastigmine and memantine improved on function and global impact in particular. Cost-effectiveness also changed. For donepezil, galantamine and rivastigmine, the incremental cost per quality-adjusted life year (QALY) in 2004 was above £50,000; in 2010 the same drugs 'dominated' best supportive care (improved clinical

2013 EvidenceUpdates

267. Assessment the Efficacy of Acetyl-L-carnitine in Patient With Alzheimer's Disease

with caregiver Exclusion Criteria: possible or probable or definite vascular dementia according to NINDS-AIREN standard CNS disease(Cerebrovascular diseases, Epilepsy etc) to cause dementia Illiteracy Patient taking galantamine, memantine, rivastigmine within three months Patient taking brain enhancer, thyroid hormone within 4 weeks Patient taking Central nervous system stimulant, Antipsychotic agent, anticholinergic agent within 2 weeks at screenig blood test: AST, ALT≥ 3 X upper limit of normal range or Hb

2016 Clinical Trials

268. Reshaping the Path of Vascular Cognitive Impairment (VCI)

) score less than 26 at screening; MMSE (5) score of > 20 at screening; Community-dwelling; Lives in Metro Vancouver; Able to comply with scheduled visits, treatment plan, and other trial procedures; Must be able to read, write, and speak English in which psychometric tests are provided with acceptable visual and auditory acuity; Stable on a fixed dose of cognitive medications (e.g., donepezil, galantamine, rivastigmine, memantine, etc.) that is not expected to change during the 12-month study period

2016 Clinical Trials

269. Feasibility and Effects of Valaciclovir Treatment in Persons With Early Alzheimer's Disease

disorders e.g. severe white matter changes or previous brain infarction will not be included but those with white matter changes considered normal for their age can be included. Positive for anti-HSV (Herpes Simplex Virus) Immunoglobulin G (IgG) in plasma, i.e. carrier of HSV. Hetero or Homozygote for allele 4 of gene Apolipoprotein E. Stable over all medication including medication for Alzheimer's disease (rivastigmine, galantamin, donepezil or memantin) for at least one month. No known allergy

2016 Clinical Trials

270. Mindful Meditation for Chronic Stroke

to ensure intact comprehension and ability to follow instructions are community-dwelling live in Greater Vancouver area able to comply with scheduled visits, treatment plan, and other trial procedures read, write, and speak English with acceptable visual and auditory acuity not expected to start or are stable on a fixed dose of cognitive medications (e.g., donepezil, galantamine, etc.) during the study period able to walk for a minimum of six metres with rest intervals with or without assistive devices

2016 Clinical Trials

271. Dosage and Efficacy of Probucol-induced apoE to Negate Cognitive Deterioration

Past or present use of a commercially available acetyl-cholinesterase inhibitor including tacrine, donepezil, rivastigmine, or galantamine Past or present use of memantine or other approved cognitive enhancement prescription agent History of heart disease, myocardial infarction or documented acute coronary syndrome, or arrhythmia (including atrial fibrillation) Corrected QT interval using Bazett's formula (QTcB) interval > 450 msec for males or 470 msec for females as detected by EKG and confirmed

2016 Clinical Trials

272. Reshaping the Path of Mild Cognitive Impairment by Refining Exercise Prescription

as the self-reported feeling of memory worsening with an onset within the last 5 years, as determined by interview and corroborated by an informant Have a baseline Montreal Cognitive Assessment (MoCA) score < 26/30 Mini-Mental State Examination (MMSE) score > 24 at screening Read, write, and speak English Not expected to start or are stable on a fixed dose of anti-dementia medications (e.g., donepezil, galantamine, etc.) during the 6-month intervention period Able to walk independently Must

2016 Clinical Trials

273. NextStep:Study to Evaluate Safety,Efficacy & Tolerability of Rivastigmine Patch in Mild to Moderate Alzheimer's Patients.

and Tolerability of Rivastigmine Patchwith 1-step Titration in Patients With Mild to Moderate Alzheimer's Disease (MMSE 10 - 23) Switched Directly From Holinesterase Inhibitors (Donepezil, Galantamine) Actual Study Start Date : May 9, 2016 Actual Primary Completion Date : May 7, 2018 Actual Study Completion Date : May 7, 2018 Resource links provided by the National Library of Medicine related topics: related topics: available for: resources: Arms and Interventions Go to Arm Intervention/treatment Rivastigmine (...) ) or single photon emission computed tomography (SPECT) was met diagnosis criteria conducted within 3 years prior to baseline visit, as long as in the past a brain scan (MRI or CT) also was met. MMSE score of ≥ 10 and ≤ 23 at screening and baseline. Patients are currently on the oral monotherapy (donepezil, 5 mg), or galantamine (16-24 mg) for 4 weeks prior to baseline visit. Patients who failed to receive enough treatment benefit from the previous treatment can be defined if the patients meet at least

2016 Clinical Trials

274. The Alzheimer's Disease THErapy With NEuroaid (ATHENE) Study

for Donepezil, 3, 4.5 or 6 mg twice daily for rivastigmine capsules, 4.6 or 9.5 mg for rivastigmine transdermal patch once daily, 8 or 12 mg twice daily for galantamine tablets, 16 to 24 mg once daily for galantamine capsules XL, 10 mg OD or 10 mg BD for Memantine) Patient or legal representative is able to provide informed consent Exclusion Criteria: Patients receiving any investigational product within 60 days or 5 half-lives prior to screening Any serious medical or psychiatric condition which

2016 Clinical Trials

275. COMPARATIVE EFFECTIVENESS OF MCI and DEMENTIA TREATMENTS IN A COMMUNITY-BASED DEMENTIA PRACTICE

of death ] Other Outcome Measures: Medications - prescribed [ Time Frame: Ordered ar Initial office visit and any subsequent visits for Ordered at initial and subsequent office visits for 96 months, until patient left the practice, or until date of death ] Initiation, duration of use, dosing levels, adverse side effects, discontinuation/reason for discontinuation of prescribed dementia medications or other drugs, including but not limited to donepezil, rivastigmine, galantamine, memantine, methlyfolate

2016 Clinical Trials

276. A Validation Study of the Novel Application of Telehealth in Clinical Drug Development in Subjects With Mild Cognitive Deficits

4 weeks prior to Screening Visit 1 or use of AD medications (including but not limited to donepezil, rivastigmine, galantamine, tacrine, and memantine) at doses that have not been stable for at least 8 weeks prior to Screening Visit 1. Participation in any interventional clinical research study within 30 days prior to screening, or during study conduct In the opinion of the Investigator, presence of any other clinical conditions (e.g., life expectancy, co-existing disease) or other

2016 Clinical Trials

277. Efficacy of RIVAstigmine on Motor, Cognitive and Behavioural Impairment in Progressive Supranuclear Palsy

/balance assessments Score < 20 on the mini-mental state examination at screening Within 4 weeks of screening or during the course of the study concurrent treatment with any cholinesterase inhibitor medication (donepezil, galantamine, rivastigmine) or any cholinergic agent (agonist or antagonist) including memantine. History of deep brain stimulation surgery. Within 4 weeks of screening or during the course of the study concurrent treatment with beta blockers, any antipsychotic drugs or mood

2016 Clinical Trials

278. Trial of a Nutritional Blend to Prevent Cognitive Decline in Older Adults

>200 mg DHA per day during the last 6 months Receiving or having received in the past 3 months a physician prescribed vitamin B12, B3 or vitamin B-complex Receiving Alzheimer's Disease medication (Galantamine, Memantine Donezepil and Rivastigmine) Deprived of their liberty by administrative or judicial decision, or under guardianship or admitted to a healthcare or social institution (subjects in non-assisted living facilities could be recruited). Having participated in another clinical study

2016 Clinical Trials

279. Phase 3 Randomized Placebo Controlled Clinical Trial of Donepezil

, Alzheimer's disease, multi-infarct dementia or CVA (history of transient ischemic attack (TIA is allowed). Current use of donepezil, galantamine, rivastigmine, tacrine, memantine, methylphenidate, dextroamphetamine, or any other specific cognition enhancing drugs are not allowed. For patients who have used these medications they must not have used them within 4 weeks prior to registration. History of allergic reactions attributed to compounds of similar chemical or biologic composition to donepezil

2016 Clinical Trials

280. Studying Partial-agonists for Ethanol and Tobacco Elimination in Russians With HIV (St PETER HIV)

month a) active hallucinations; b) mental health symptoms prompting a visit to the ED or hospital; mental health medication changes due to worsening symptoms; presence of suicidal ideations) History of pheochromocytoma Taking smoking cessation medications in past 30 days History of seizures History of Buerger's disease Acute coronary syndrome within 1 month of enrollment Systolic BP > 180 mm Hg or diastolic BP > 105 mm Hg Currently taking anti-tuberculosis medications Currently taking Galantamine

2016 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>